OC
TBIO

Oppenheimer & Co’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Oppenheimer & Co’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21,959
Closed -$299K – 1430
2020
Q3 		$299K Buy
21,959
+6,857
+45% +$106K 0.01% 980
2020
Q2 		$271K Buy
+15,102
New +$228K 0.01% 1002

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Oppenheimer & Co's TBIO Position: Q4 2020 in Review

Oppenheimer & Co sold out of Translate Bio, Inc. Common Stock (TBIO) in Q4 2020, closing a stake of 21,959 shares — an estimated $299K sold.

Oppenheimer & Co first reported a position in TBIO in Q2 2020 and held it in 2 quarters. The position peaked at $299K in Q3 2020. 150 funds tracked by Wall St. Rank hold TBIO as of Q4 2020.

  • Oppenheimer & Co reported no remaining Translate Bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 21,959 Translate Bio, Inc. Common Stock shares in Q4 2020, an estimated $299K.
  • Oppenheimer & Co first reported a position in Translate Bio, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Oppenheimer & Co's Translate Bio, Inc. Common Stock position peaked at $299K in Q3 2020.
  • 150 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q4 2020.

Based on Oppenheimer & Co's 13F filing for Q4 2020, filed 11 Feb 2021.